Search research articles

Search research articles

Related Experiment Videos

Liver function and medroxyprogesterone acetate elimination in man.

Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie

|January 1, 1984

Summary

This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Future directions for monitoring and human health research for the Arctic Monitoring and Assessment Programme.

Global health action·2018

Same author

Quantitative estimation of mercury intake by toxicokinetic modelling based on total mercury levels in humans.

Environment international·2018

Same author

The xenoestrogens, bisphenol A and para-nonylphenol, decrease the expression of the ABCG2 transporter protein in human term placental explant cultures.

Molecular and cellular endocrinology·2016

Same author

Is geographical distance a barrier in the use of public primary health services among rural and urban young adults? Experience from Northern Finland.

Public health·2015

Same author

Organic anion transporter 4 (OAT 4) modifies placental transfer of perfluorinated alkyl acids PFOS and PFOA in human placental ex vivo perfusion system.

Placenta·2015

Same author

Cadmium inhibits ABCG2 transporter function in BeWo choriocarcinoma cells and MCF-7 cells overexpressing ABCG2.

Placenta·2012

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Medroxyprogesterone acetate (MPA) elimination is significantly reduced in patients with alcoholic cirrhosis. MPA clearance remains normal in fatty liver and primary biliary cirrhosis, indicating impairment only in advanced liver disease.

Area of Science:

Pharmacokinetics
Hepatology
Drug Metabolism

Background:

Liver disease significantly impacts drug metabolism and elimination.
Medroxyprogesterone acetate (MPA) is a synthetic progestin with hepatic clearance.
Assessing MPA elimination in various liver conditions is crucial for patient management.

Purpose of the Study:

To investigate the elimination rate of Medroxyprogesterone acetate (MPA) in patients with different types of liver disease.
To correlate MPA elimination with liver function indicators, including antipyrine kinetics.
To determine if liver disease severity affects MPA clearance.

Main Methods:

Radioimmunoassay (RIA) was used to measure serum and urine MPA concentrations after oral administration.

Related Experiment Videos

Biochemical liver tests were performed to assess liver function.

Antipyrine kinetics were evaluated as a marker for hepatic drug-metabolizing enzyme activity.

Main Results:

MPA elimination rate was significantly reduced in patients with alcoholic cirrhosis.
MPA elimination rates were within the normal range for patients with fatty liver and primary biliary cirrhosis.
The antipyrine test, indicating drug-metabolizing enzyme activity, was impaired exclusively in alcoholic patients.

Conclusions:

MPA elimination is impaired in patients with advanced alcoholic liver disease.
Fatty liver and primary biliary cirrhosis do not significantly affect MPA elimination.
Liver disease severity is a key factor in MPA clearance impairment.